Background: Minimal hepatic Encephalopathy (MHE) is defined as HE without symptoms on clinical/neurological examination, but with deficits in some cognitive areas that can only be measured by neuropsychometric testing. However, numerous studies have shown that, although the neurological symptoms are slight, affected patients are markedly impaired in their quality of life and ability to work. Various treatment modalities that have been shown to reverse MHE include lactulose/lactitol, probiotics/synbiotics, L-carnitine but rifaximin has shown a general trend toward better efficacy and better tolerability in patients with overt hepatic encephalopathy (OHE). Objective: Our objective is to assess the diagnostic role of minimental state examination (MMSE), electroencephalography (EEG) and visual evoked potential (VEP) in detection of MHE and to evaluate the efficacy of rifaximin in improving EEG and VEP in patients with MHE. Patients and Methods: Sixty cirrhotic patients were enrolled in the study depending on clinical evidence of stigmata of chronic liver disease, laboratory investigations including liver function tests, ultrasonographic features of liver cirrhosis and with no evidence of overt hepatic encephalopathy. Diagnois of MHE was made depending on minimental state examination (MMSE) and neurophysiological tools including EEG and VEP. A control group of sixty healthy volunteers with age and sex matched were included. The patient group received Rifaximin 550 mg twice daily for 8 weeks then follow up EEG and VEP studies were done. Results: MHE was detected in 36.7%, 48.3%, 51.7% of our series based on MMSE, EEG and VEP respectively. Child Pouph A, B, C was found in 51.7%, 35%, 13.3% respectively. Rifaximin was well tolerated. At the end of treatment, EEG and VEP studies were done which showed signficant changes between pre and post treatment results (P value = 0.03, 0.001, <0.001). Conclusion: MMSE as well as EEG and VEP were reasonable diagnostic tools for early detection of MHE particularly in countries with low level of education. Rifaximin significantly improves both EEG and VEP in cirrhotic patients with MHE.
References
[1]
Ferenci, P., Lockwood, A., Mullen, K., Tarter, R., Weissenborn, K. and Blei, A.T. (2002) Hepatic Encephalopathy—Definition, Nomenclature, Diagnosis, and Quantification: Final Report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology, 35, 716-721. https://doi.org/10.1053/jhep.2002.31250
[2]
Sarin, S. and Nundy, S. (1985) Subclinical Encephalopathy after Portosystemic Shunts in Patients with Non-Cirrhotic Portal Fibrosis. Liver, 5, 142-146. https://doi.org/10.1111/j.1600-0676.1985.tb00229.x
[3]
Dhiman, R.K. and Chawla, Y.K. (2009) Minimal Hepatic Encephalopathy. Indian Journal of Gastroenterology, 28, 5-16. https://doi.org/10.1007/s12664-009-0003-6
[4]
Bajaj, J.S., Hafeezullah, M., Hoffmann, R.G. and Saeian, K. (2007) Minimal Hepatic Encephalopathy: A Vehicle for Accidents and Traffic Violations. The American Journal of Gastroenterology, 102, 1903-1909. https://doi.org/10.1111/j.1572-0241.2007.01424.x
[5]
Schomerus, H. and Hamster, W. (2001) Quality of Life in Cirrhotics with Minimal Hepatic Encephalopathy. Metabolic Brain Disease, 16, 37-41. https://doi.org/10.1023/A:1011610427843
[6]
Bajaj, J.S., Hafeezullah, M., Hoffmann, R.G., Varma, R.R., Franco, J., Binion, D.G., et al. (2007) Navigation Skill Impairment: Another Dimension of the Driving Difficulties in Minimal Hepatic Encephalopathy. Hepatology, 47, 596-604. https://doi.org/10.1002/hep.22032
[7]
Sharma, P., Sharma, B.C., Puri, V. and Sarin, S.K. (2008) An Open-Label Randomized Controlled Trial of Lactulose and Probiotics in the Treatment of Minimal Hepatic Encephalopathy. European Journal of Gastroenterology & Hepatology, 20, 506-511. https://doi.org/10.1097/MEG.0b013e3282f3e6f5
[8]
Maclayton, D.O. and Eaton-Maxwell, A. (2009) Rifaximin for Treatment of Hepatic Encephalopathy. Annals of Pharmacotherapy, 43, 77-84. https://doi.org/10.1345/aph.1K436
[9]
Tarter, R.E., Hegedus, A.M., van Thiel, D.H., Schade, R.R., Gavaler, J.S. and Starzl, T.E. (1984) Nonalcoholic Cirrhosis Associated With Neuropsychological Dysfunction in the Absence of Overt Evidence of Hepatic Encephalopathy. Gastroenterology, 86, 1421-1427.
[10]
Weissenborn, K., Ennen, J.C., Schomerus, H., Rückert, N. and Hecker, H. (2001) Neuropsychological Characterization of Hepatic Encephalopathy. Journal of Hepatology, 34, 768-773. https://doi.org/10.1016/S0168-8278(01)00026-5
[11]
Bajaj, J., Cordoba, J., Mullen, K., Amodio, P., Shawcross, D., Butterworth, R., et al. (2011) The Design of Clinical Trials in Hepatic Encephalopathy—An International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) Consensus Statement. Alimentary Pharmacology & Therapeutics, 33, 739-747. https://doi.org/10.1111/j.1365-2036.2011.04590.x
[12]
Schiff, S., D’Avanzo, C., Cona, G., Goljahani, A., Montagnese, S., Volpato, C., et al. (2014) Insight into the Relationship between Brain/Behavioral Speed and Variability in Patients with Minimal Hepatic Encephalopathy. Clinical Neurophysiology, 125, 287-297. https://doi.org/10.1016/j.clinph.2013.08.004
[13]
Folstein, M.F., Folstein, S.E. and McHugh, P.R. (1975) “Mini-Mental State”: A Practical Method for Grading the Cognitive State of Patients for the Clinician. Journal of Psychiatric Research, 12, 189-198. https://doi.org/10.1016/0022-3956(75)90026-6
[14]
Montagnese, S., Gordon, H.M., Jackson, C., Smith, J., Tognella, P., Jethwa, N., et al. (2005) Disruption of Smooth Pursuit Eye Movements in Cirrhosis: Relationship to Hepatic Encephalopathy and Its Treatment. Hepatology, 42, 772-781. https://doi.org/10.1002/hep.20855
[15]
Koziarska, D., Wunsch, E., Milkiewicz, M., Wójcicki, M., Nowacki, P. and Milkiewicz, P. (2013) Mini-Mental State Examination in Patients with Hepatic Encephalopathy and Liver Cirrhosis: A Prospective, Quantified Electroencephalography Study. BMC Gastroenterology, 13, 107. https://doi.org/10.1186/1471-230X-13-107
[16]
Conn, H., Leevy, C., Vlahcevic, Z., Rodgers, J., Maddrey, W., Seeff, L., et al. (1977) Comparison of Lactulose and Neomycin in the Treatment of Chronic Portal-Systemic Encephalopathy: A Double Blind Controlled Trial. Gastroenterology, 72, 573-783.
[17]
Thabut, D., Kinugawa, K. and Weiss, N. (2014) Diagnosis of Minimal Hepatic Encephalopathy in Patients with Cirrhosis: Should We Bury Psychometric Tests? Hepatology, 59, 2428. https://doi.org/10.1002/hep.26967
[18]
Amodio, P. and Montagnese, S. (2015) Clinical Neurophysiology of Hepatic Encephalopathy. Journal of Clinical & Experimental Hepatology, 5, S60-S68. https://doi.org/10.1016/j.jceh.2014.06.007
[19]
Pugh, R., Murray-Lyon, I., Dawson, J., Pietroni, M. and Williams, R. (1973) Transection of the Oesophagus for Bleeding Oesophageal Varices. British Journal of Surgery, 60, 646-649. https://doi.org/10.1002/bjs.1800600817
[20]
Mungas, D. (1991) Iii-Office Mental Status Testing: A Practical Guide. Geriatrics, 46, 54-67.
[21]
Kochhann, R., Cerveira, M.O., Godinho, C., Camozzato, A. and Chaves, M.L.F. (2009) Evaluation of Mini-Mental State Examination Scores According to Different Age and Education Strata, and Sex, in a Large Brazilian Healthy Sample. Dementia & Neuropsychologia, 3, 88-93. https://doi.org/10.1590/S1980-57642009DN30200004
[22]
Lourenço, R.A. and Veras, R.P. (2006) Mini-Mental State Examination: Psychometric Characteristics in Elderly Outpatients. Revista de Saúde Pública, 40, 712-719. https://doi.org/10.1590/S0034-89102006000500023
[23]
Kochhann, R., Varela, J.S., de Macedo Lisboa, C.S. and Chaves, M.L.F. (2010) The Mini Mental State Examination: Review of Cutoff Points Adjusted for Schooling in a Large Southern Brazilian Sample. Dementia & Neuropsychologia, 4, 35-41. https://doi.org/10.1590/S1980-57642010DN40100006
[24]
Parsons-Smith, B., Summerskill, W., Dawson, A. and Sherlock, S. (1957) The Electroencephalograph in Liver Disease. The Lancet, 270, 867-871. https://doi.org/10.1016/S0140-6736(57)90005-3
[25]
Child, C. and Turcotte, J. (1964) Surgery in Portal Hypertension. Major Problems in Clinical Surgery: The Liver and Portal Hypertension. Saunders, Philadelphia.
[26]
Epstein, C. (2006) American Clinical Neurophysiology Society Guideline 5: Guidelines for Standard Electrode Position Nomenclature. Journal of Clinical Neurophysiology, 23, 107-110. https://doi.org/10.1097/00004691-200604000-00006
[27]
Tandon, O. and Sharma, K. (1989) Visual Evoked Potential in Young Adults: A Normative Study. Indian Journal of Physiology and Pharmacology, 33, 247-249.
[28]
Weissenborn, K., Giewekemeyer, K., Heidenreich, S., Bokemeyer, M., Berding, G. and Ahl, B. (2005) Attention, Memory, and Cognitive Function in Hepatic Encephalopathy. Metabolic Brain Disease, 20, 359-367. https://doi.org/10.1007/s11011-005-7919-z
[29]
Mina, A., Moran, S., Ortiz-Olvera, N., Mera, R. and Uribe, M. (2014) Prevalence of Minimal Hepatic Encephalopathy and Quality of Life in Patients with Decompensated Cirrhosis. Hepatology Research, 44, E92-E99. https://doi.org/10.1111/hepr.12227
[30]
Nardone, R., Taylor, A.C., Höller, Y., Brigo, F., Lochner, P. and Trinka, E. (2016) Minimal Hepatic Encephalopathy: A Review. Neuroscience Research, 111, 1-12. https://doi.org/10.1016/j.neures.2016.04.009
[31]
Torres, D., Abrantes, J. and Brandão-Mello, C. (2013) Cognitive Assessment of Patients with Minimal Hepatic Encephalopathy in Brazil. Metabolic Brain Disease, 28, 473-483. https://doi.org/10.1007/s11011-013-9405-3
[32]
Montagnese, S., Biancardi, A., Schiff, S., Carraro, P., Carla, V., Mannaioni, G., et al. (2011) Different Biochemical Correlates for Different Neuropsychiatric Abnormalities in Patients with Cirrhosis. Hepatology, 53, 558-566. https://doi.org/10.1002/hep.24043
[33]
Amodio, P., Del Piccolo, F., Pettenò, E., Mapelli, D., Angeli, P., Iemmolo, R., et al. (2001) Prevalence and Prognostic Value of Quantified Electroencephalogram (EEG) Alterations in Cirrhotic Patients. Journal of Hepatology, 35, 37-45. https://doi.org/10.1016/S0168-8278(01)00129-5
[34]
Caspers, H. (1983) Electroencephalography: Basic Principles, Clinical Applications and Related Fields. Ernst Niedermeyer, Fernando Lopes da Silva. The Quarterly Review of Biology, 58, 301-302. https://doi.org/10.1086/413356
[35]
Sandford, N.L. and Saul, R.E. (1988) Assessment of Hepatic Encephalopathy with Visual Evoked Potentials Compared with Conventional Methods. Hepatology, 8, 1094-1098. https://doi.org/10.1002/hep.1840080519
[36]
Chamuleau, R., Deutz, N., De Haan, J. and Van Gool, J. (1987) Correlation between Electroencephalographic and Biochemical Indices in Acute Hepatic Encephalopathy in Rats. Journal of Hepatology, 4, 299-306. https://doi.org/10.1016/S0168-8278(87)80538-X
[37]
Egberts, E., Schomerus, H., Hamster, W. and Jürgens, P. (1985) Branched Chain Amino Acids in the Treatment of Latent Portosystemic Encephalopathy: A Double- Blind Placebo-Controlled Crossover Study. Gastroenterology, 88, 887-895. https://doi.org/10.1016/S0016-5085(85)80004-4
[38]
Pedretti, G., Calzetti, C., Missale, G. and Fiaccadori, F. (1991) Rifaximin versus Neomycin on Hyperammoniemia in Chronic Portal Systemic Encephalopathy of Cirrhotics. A Double-Blind, Randomized Trial. The Italian Journal of Gastroenterology, 23, 175-178.
[39]
Shawcross, D.L., Davies, N.A., Williams, R. and Jalan, R. (2004) Systemic Inflammatory Response Exacerbates the Neuropsychological Effects of Induced Hyperammonemia in Cirrhosis. Journal of Hepatology, 40, 247-254. https://doi.org/10.1016/j.jhep.2003.10.016
[40]
Leevy, C.B. and Phillips, J.A. (2007) Hospitalizations during the Use of Rifaximin versus Lactulose for the Treatment of Hepatic Encephalopathy. Digestive Diseases and Sciences, 52, 737-741. https://doi.org/10.1007/s10620-006-9442-4
[41]
Jiang, Q., Jiang, X.-H., Zheng, M.-H., Jiang, L.-M., Chen, Y.-P. and Wang, L. (2008) Rifaximin versus Nonabsorbable Disaccharides in the Management of Hepatic Encephalopathy: A Meta-Analysis. European Journal of Gastroenterology & Hepatology, 20, 1064-1070. https://doi.org/10.1097/MEG.0b013e328302f470
